Tata Elxsi has introduced AnaTel, a cutting-edge AI development platform tailored for the healthcare sector, aiming to significantly expedite software development timelines.
This platform, co-created with OpenAna, is designed to meet increasing regulatory demands by integrating autonomous AI agents into engineering workflows. Unveiled at DeviceTalks Boston 2026, AnaTel can potentially cut development cycles by up to 60%, addressing the operational hurdles that medtech software teams face, particularly with stringent requirements from regulatory bodies like the FDA and MDCG.
AnaTel streamlines the AI-Driven Software Delivery Lifecycle by automating the generation of code, documentation, test cases, and essential regulatory artifacts. Notably, it facilitates eSTAR-aligned submission preparation, which could reduce the development timeline for Software as a Medical Device (SaMD) from eight weeks to just 72 hours.
The platform operates as a customizable AI software team, leveraging a specialized agent focused on healthcare and life sciences. Key features include the generation of regulatory-grade documentation, support for traceability matrices, and expedited change assessments, all of which are critical in regulated environments.
This initiative reflects Tata Elxsi’s commitment to enhancing software engineering efficiency in the healthcare sector while ensuring compliance. The collaboration with OpenAna emphasizes lifecycle traceability and safety, showcasing the potential for AI to transform medtech development processes.